Expert Review: Kratom Alkaloids Can Significantly Alter Medication Effects via CYP Enzyme Inhibition

Why it matters

This expert review provides clinicians with critical information on how kratom's bioactive alkaloids interact with commonly prescribed medications. Understanding these interactions is essential for patient safety, especially among those taking opioids, antidepressants, or benzodiazepines.

The big picture

Kratom contains mitragynine and 7-hydroxymitragynine, which interact with liver enzymes (CYP450) responsible for metabolizing many drugs. These interactions can increase drug concentrations or reduce therapeutic efficacy, creating risks for overdose or treatment failure.

Key findings

• Kratom alkaloids interact with pharmacokinetic and pharmacodynamic processes of concurrent medications
• CYP450 enzyme inhibition can elevate blood levels of drugs metabolized by these pathways
• Clinically significant interactions documented with opioids, antidepressants, benzodiazepines, and stimulants
• High-potency 7-OH products carry greater interaction risk than traditional leaf
• Healthcare providers lack standardized protocols for assessing kratom-drug interactions

What they say

"Evaluating drug interactions in kratom usage is clinically imperative because kratom's bioactive alkaloids can interact with the pharmacokinetic and pharmacodynamic processes of concurrent medications, potentially resulting in adverse effects or compromised therapeutic outcomes." - Expert authors

Bottom line

**Kratom users taking prescription medications face real risks from enzyme inhibition; clinicians should screen for concurrent use and monitor for signs of drug accumulation.**